NCT06066346 · Memorial Sloan Kettering Cancer Center
A Study of Talquetamab for People with Multiple Myeloma Who Have Received BCMA CAR T-Cell Therapy
What this study is about
The researchers are doing this study to find out whether talquetamab is an effective treatment after BCMA CAR Tcell therapy for people with relapsed or refractory multiple myeloma. All participants in this study will have already received the BCMA CAR T-cell therapy ide-cel for their disease.
View original scientific description
The researchers are doing this study to find out whether talquetamab is an effective treatment after BCMA CAR Tcell therapy for people with relapsed or refractory multiple myeloma. All participants in this study will have already received the BCMA CAR T-cell therapy ide-cel for their disease.
Interventions
DRUG
Talquetamab
Talquetamab will be administered SC until disease progression
Primary outcome measures
Overall Response Rate (ORR)
Time frame: up to 2 years
ORR is defined as the proportion of participants who have a partial response (PR) or better according to the international myeloma working group (IMWG) criteria.
Who can participate
This study lists these criteria on ClinicalTrials.gov. A study coordinator reviews eligibility during screening — this page does not determine whether you qualify.
Inclusion criteria
- Patient with multiple myeloma who has received prior treatment with an IMID, PI, and a CD38 monoclonal antibody
- Received treatment with an FDA approved BCMA CART cell therapy ide-cel within 1-3 months prior to enrollment
- Serum monoclonal protein \< 0.5 gm/dL; 24-hour urine monoclonal protein \< 200 mg; and serum involved free light chains \< 10 mg/dL
- No evidence of disease progression based on IMWG criteria
- ≥18 years of age at the time of signing informed consent.
- ECOG performance status of 0 or 1
- Recovered to Grade 1 or baseline of any non-hematologic toxicities due to prior treatments, excluding Grade 2 neuropathy and Grade 2 alopecia.
- No evidence of ongoing, any grade cytokine release syndrome or immune effector cell mediated neurotoxicity
- No additional myeloma therapies after the CART cell therapy
- Absolute neutrophil count (ANC) ≥ 1,000/mm\^3 without growth factor support for 7 days for G-CSF or GM-CSF and for 14 days for pegylated GCSF prio
Where
- Basking Ridge, New Jersey
- Middletown, New Jersey
- Montvale, New Jersey
- Commack, New York
- Harrison, New York
- New York, New York
- Uniondale, New York
Collaborators
Janssen Pharmaceuticals
Related conditions & keywords
Frequently asked questions
What is a clinical trial?
A clinical trial is a research study that tests new medical treatments, drugs, devices, or procedures to determine their safety and effectiveness. Trials are carefully designed and monitored to protect participants while advancing medical knowledge.
Is it safe to participate?
Clinical trials follow strict safety guidelines and ethical standards. Trials must be reviewed and approved, and participants are closely monitored by medical professionals throughout the study. You can withdraw at any time if you choose.
Will I be compensated?
Many clinical trials offer compensation for your time, travel expenses, and inconvenience. The specific compensation varies by study and will be discussed during the screening process. All study-related medical care is typically provided at no cost to participants.
Will I receive a placebo instead of treatment?
When effective treatment exists, participants typically receive either the standard treatment plus the study intervention, or the standard treatment plus placebo. You would not be denied effective care. Placebos are primarily used when no proven treatment is available, or in addition to standard care. Your trial consent form will clearly explain what treatments you may receive.
Can I leave a trial if I change my mind?
Absolutely. Participation in clinical trials is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty or loss of benefits to which you are otherwise entitled.
How long does a clinical trial last?
Trial duration varies widely depending on the study design and purpose. Some trials last just a few weeks, while others may continue for months or years. The study coordinator will provide specific timeline information during your screening call.
Data: ClinicalTrials.gov · synced Mar 4, 2026 · Source of record for eligibility and locations